## Michigan Prior Authorization Request Form For Prescription Drugs Instructions

## Important: Please read all instructions below before completing FIS 2288.

Section 2212c of Public Act 218 of 1956, MCL 500.2212c, requires the use of a standard prior authorization form when a policy, certificate or contract requires prior authorization for prescription drug benefits.

A standard form, FIS 2288, is being made available by the Department of Insurance and Financial Services to simplify exchanges of information between prescribers and health insurers as part of the process of requesting prescription drug prior authorization. This form will be updated periodically and the form number and most recent revision date are displayed in the top left-hand corner.

- > This form is made available for use by prescribers to initiate a prior authorization request with the health insurer.
- ➤ Prior authorization requests are defined as requests for pre-approval from an insurer for specified medications or quantities of medications before they are dispensed.
- > "Prescriber" means the term as defined in section 17708 of the Public Health Code, 1978 PA 368, MCL
- > 333,17708.
- ➤ "Prescription drug" means the term as defined in section 17708 of the Public Health Code, 1978 PA 368, MCL 333.17708.
- ➤ Pursuant to MCL 500.2212c, prescribers and insurers must comply with required timeframes pertaining to the processing of a prior authorization request. Insurers may request additional information or clarification needed to process a prior authorization request.
- ➤ The prior authorization is considered granted if the insurer fails to grant the request, deny the request, or require additional information of the prescriber within 72 hours after the date and time of submission of an expedited prior authorization request or within 15 days after the date and time of submission of a standard prior authorization request. If additional information is requested by an insurer, a prior authorization request is considered to have been granted by the insurer if the insurer fails to grant the request, deny the request, or otherwise respond to the request of the prescriber within 72 hours after the date and time of submission of the additional information for an expedited prior authorization request; or within 15 days after the date and time of submission of the additional information for standard prior authorization request.
- The prior authorization is considered void if the prescriber fails to submit the additional information within 5 days after the date and time of the original submission of a properly completed expedited prior authorization request or within 21 days after the date and time of the original submission of a properly completed standard prior authorization request.
- ➤ In order to designate a prior authorization request for expedited review, a prescriber must certify that applying the 15-day standard review period may seriously jeopardize the life and health of the patient or the patient's ability to regain maximum function.

PRESCRIBERS, PLEASE SUBMIT THIS FORM TO THE PATIENT'S HEALTH PLAN ONLY. Please do not send to the department.

Only provide the physician's direct contact number and initials if you are requesting an Expedited Review Request.

## Michigan Prior Authorization Request Form for Prescription Drugs Fax: 800-424-7648

(PRESCRIBERS SUBMIT THIS FORM TO THE PATIENT'S HEALTH PLAN)

☐ Standard Review Request	
☐ Expedited Review Request: I hereby certify that a standard revies jeopardize the life or health of the patient or the patient's ability to	
Physician's Direct Contact Phone Number:	Initials:
A) Reason for Request  ☐ Initial Authorization Request ☐ Renewal Request ☐ DA	AW
B) Patient Demographics	
Is patient hospitalized: ☐ Yes ☐ No	
Patient Name:	DOB:
Patient Health Plan ID:	
C) Pharmacy Insurance Plan	
☐ Priority ☐ Magellan ☐ Blue Cross Blue Shield of Michigan	☐ HAP ☑ University of Michigan Prescription Drug Plar
☐ Total Health Care ☐ Blue Care Network ☐ HealthPlus of I	Michigan
D) Prescriber Information	
Prescriber Name: NPI:	Specialty:
DEA (required for controlled substance requests only):	
Contact Name: Contact Phone:	Contact Fax:
Health Plan Provider ID (if accessible):	
E) Pharmacy Information (optional)	
Pharmacy Name: Pharmac	cyTelephone:
F) Requested Prescription Drug Information	
Drug Name: Stre	ength:
Dosing Schedule: Dur	ration:
Diagnosis (specific) with ICD#:	
Place of infusion/injection (if applicable):	
Facility Provider ID/NPI:	
Has the patient already started the medication? ☐ Yes ☐ No	o If so, when?

disclosed. A person ndefraud is provided.  Physician's Name:  Physician's Signate  Date:  PA 218 of 1956 as ame	ure: ended requires the ior authorization for	use of a standard prior prescription drug bene LOB: Denie	authorization for fits.  e Only*  d:	
disclosed. A person in defraud is provided.  Physician's Name:  Physician's Signate  Date:  PA 218 of 1956 as ame health plan requires pride in the provided i	ure:ended requires the ior authorization for	use of a standard prior prescription drug bene LOB: Denie	authorization for fits.  e Only*  d:	ormation with the intent to
disclosed. A person in defraud is provided.  Physician's Name:  Physician's Signation Date:  PA 218 of 1956 as amendalth plan requires principle.  Request Date:	ure: ended requires the ior authorization for	use of a standard prior prescription drug bene cor Health Plan Us	authorization fo	ormation with the intent to
disclosed. A person redefraud is provided.  Physician's Name:  Physician's Signate  Date:  PA 218 of 1956 as ame health plan requires pri	ure: ended requires the ior authorization for	use of a standard prior prescription drug bene	authorization fo	ormation with the intent to
disclosed. A person nation defraud is provided.  Physician's Name:  Physician's Signate  Date:  PA 218 of 1956 as ame	ure:ended requires the ior authorization for	use of a standard prior	or deceptive inf	ormation with the intent to
disclosed. A person in defraud is provided.  Physician's Name:  Physician's Signation Date:  PA 218 of 1956 as ame	ure:ended requires the ior authorization for	use of a standard prior	or deceptive inf	ormation with the intent to
disclosed. A person redefraud is provided.  Physician's Name:  Physician's Signate  Date:	may be committing i	insurance fraud if false	or deceptive inf	ormation with the intent to
disclosed. A person n defraud is provided. Physician's Name: Physician's Signat	may be committing i	insurance fraud if false	or deceptive inf	ormation with the intent to
disclosed. A person n defraud is provided. Physician's Name:	may be committing i	insurance fraud if false	or deceptive inf	ormation with the intent to
disclosed. A person need defraud is provided.	may be committing i	insurance fraud if false	or deceptive inf	
disclosed. A person n			•	,
relevant diagnost additional information	tic labs, measures ation that may be	of response to treatr necessary for review	ment, etc.) Ple . Please note	ormation is necessary such as ease refer to plan's website for that sending this form with r adverse determination.
Drug Name	Strength	Dosing Schedule	Duration	Adverse Event/Specific Failure
H) Failed/Contrair	ndicated Thera	pies		
		assist with the review		chart notes to support your

G) Rationale for Prior Authorization: (e.g., information such as history of present illness, past



DIFS Is an equal opportunity employer/program.

Auxiliary aids, services and other reasonable accommodations are available upon request to individuals with disabilities. Phone DIFS toll-free at: 877-999-6442

Visit DIFS online at: www.michigan.gov/difs





Member's Last Name:					 Men	ıber'	s Fir	st Na	me:											

## University of Michigan - Medically Necessary for Brand

Some of the information needed to make a determination for coverage is not specifically requested on the Michigan Prior Authorization Request Form for Prescription Drugs. To avoid delays in reviewing your request, please make sure to include all of the following information.

Initial Request					
Does the requested product not have a commercially available authorized generic* <b>AND</b> meet <b>one</b> of the following criteria:					
A. The requested product is an FDA-recognized narrow therapeutic index (NTI) product†; OR					
B. The requested product is used in the treatment of seizure disorders, is not a benzodiazepine, and has not yet been evaluated for NTI status‡; <b>OR</b>					
C. The member has tried generic equivalents from at least two different manufacturers, or from one manufacturer if only one is available on market, and <b>both</b> of the following criteria are met:					
The member has experienced one or more of the following outcomes from each generic equivalent of the requested brand medication:					
<ul> <li>Life-threatening adverse reaction</li> </ul>					
<ul> <li>Documented allergic response</li> </ul>					
<ul> <li>Therapeutic failure, confirmed by measurable outcomes, while taking the generic equivalent</li> </ul>					
<ul> <li>The patient, provider, or pharmacy has completed a MedWatch form (Form 3500/3500B) for each generic product tried and failed.</li> </ul>					

- \* A current list of authorized generic drugs is maintained by the FDA and available at this URL: <a href="https://www.fda.gov/about-fda/center-drug-evaluation-and-research-cder/fda-listing-authorized-generics">https://www.fda.gov/about-fda/center-drug-evaluation-and-research-cder/fda-listing-authorized-generics</a>
  If an authorized generic is currently in shortage, the request may proceed as though the authorized generic is available. If approved, these requests are limited to 6 months (see Coverage Duration). If the authorized generic is still not available after 6 months, these requests may be approved for an additional 6 months.
- † Products that have been identified as NTI should automatically process without a DAW penalty when a DAW code of "1" is applied. As of June 2023, the following products have been identified as NTI and should process without a DAW penalty: carbamazepine, cyclosporine modified, digoxin, levothyroxine, liothyronine, phenytoin, tacrolimus, valproic acid, and warfarin. The plan will continue to monitor and adjust this list as necessary.
- ‡ For products identified as NTI by the requestor but not included on the plan's automatic bypass list, the request must include evidence or supporting material that the product is an FDA-recognized NTI product.

Continued on next page.





Member's Last Name:						
Renewal Request						
Does the member's provider attest that the brand medication is still medically necessary?						
The requested product does not have an authorized gener	ric available. Is this statement <b>TRUE</b> ?	Υ	N			

University of Michigan Prescription Drug Plan Pharmacy Services Portal: https://umich.magellanrx.com/

©2021–2024 by Magellan Rx Management, LLC. All rights reserved. Revised: 02/29/2024 | Effective: 10/19/2023